Home/Pipeline/DT-101

DT-101

Major Depressive Disorder (MDD)

Phase 2Active

Key Facts

Indication

Major Depressive Disorder (MDD)

Phase

Phase 2

Status

Active

Company

Draig Therapeutics

About Draig Therapeutics

Draig Therapeutics is a private, Cambridge-based biotech that emerged from stealth in mid-2025 with a substantial $140 million Series A financing to advance its pipeline of novel neuromodulators. The company is led by a seasoned team, including CEO Ivana Magovčević-Liebisch and Board Chair Douglas E. Williams, and is backed by a top-tier investor syndicate. With a clear focus on addressing the significant unmet need in neuropsychiatry, Draig's strategy centers on developing best-in-class modulators of glutamate and GABA receptors, aiming to deliver transformative treatments for conditions like MDD.

View full company profile

Therapeutic Areas

Neuropsychiatry Major Depressive Disorder

Other Major Depressive Disorder (MDD) Drugs

Drug	Company	Phase	Status
AL001	Alzamend Neuro	Preclinical	Research
Deep TMS (H1 Coil)	BrainsWay	FDA Cleared	Commercial
EXXUA™ (gepirone ER)	Aytu BioPharma	Commercial	Launched
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
INV-202 (Oral & LAI)	Indivior	Preclinical	Discovery
NeuroStar Advanced Therapy	Neuronetics	FDA Cleared	Commercial
Gepirone ER	Fabre-Kramer Pharmaceuticals	NDA Submitted	Active
Exablate Neuro	Insightec	Clinical Trial	Active
BrightKaire Platform for Depression	NeuroKaire	Pre-clinical	Active
Tyemvers (CKDB-501)	Healis Therapeutics	Pre-clinical	Active
VENTURA-7	New Hope Clinical Research	Phase 2/3	Active
Major Depressive Disorder Program	Actipulse Neuroscience	Phase 3	Active